Fresenius Medical Care Habersham is a medicare approved dialysis facility center in Demorest, Georgia and it has 11 dialysis stations. It is located in Habersham county at 735 N Historic Hwy 441, Demorest, GA, 30535. You can reach out to the office of Fresenius Medical Care Habersham at (706) 839-1761. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Medical Care Habersham has the following ownership type - Profit. It was first certified by medicare in July, 2008. The medicare id for this facility is 112800 and it accepts patients under medicare ESRD program.
| Name | Fresenius Medical Care Habersham |
|---|---|
| Location | 735 N Historic Hwy 441, Demorest, Georgia |
| No. of Dialysis Stations | 11 |
| Medicare ID | 112800 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 735 N Historic Hwy 441, Demorest, Georgia, 30535 | |
| (706) 839-1761 | |
| Not Available |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
| NPI Number | 1144490889 |
| Organization Name | Fresenius Medical Care Habersham |
| Doing Business As | Fresenius Medical Care Kidney Healthcare, Llc |
| Address | 735 North Historic Hwy 441 Demorest, Georgia, 30535 |
| Phone Number | (706) 839-1761 |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 39 |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 60 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 595 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Medical Care Habersham with elevated calcium levels.
| Patients with hypercalcemia | 68 |
| Hypercalcemia patient months | 673 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 69 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 53 |
| Patient months included in arterial venous fistula and catheter summaries | 483 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.
Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) could lead to the development of new and better treatments for broken bones and other orthopaedic problems associated with ageing.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton® products in China, today announced that it was honored to receive the Shenzhen Baoan District Quality Award from the Market Supervision Administration of Shenzhen Municipality.
Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.
› Verified 4 days ago